Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

How far can $24 mil­lion get you? For Wash­ing­ton-based Bi­o­Life So­lu­tions, the an­swer is all the way to In­di­anapo­lis.

Bi­o­Life So­lu­tions, a top provider of tools and ser­vices for cell and gene ther­a­py de­vel­op­ment, is putting down a mod­est $24 mil­lion to snap up all the shares in Sex­ton Biotech­nolo­gies it doesn’t al­ready own, the part­ners said on Mon­day. In the process, it’s get­ting a slate of new bio­pro­duc­tion tools, and the deed to Sex­ton’s down­town In­di­anapo­lis fa­cil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER